Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Elucidating distinct roles for NF1 in melanomagenesis.

Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K.

Cancer Discov. 2013 Mar;3(3):338-49. doi: 10.1158/2159-8290.CD-12-0313. Epub 2012 Nov 21.

2.

An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance.

Gibney GT, Smalley KS.

Cancer Discov. 2013 Mar;3(3):260-3. doi: 10.1158/2159-8290.CD-13-0017.

3.

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.

Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.

Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.

4.

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE, Garraway LA.

Cancer Discov. 2013 Mar;3(3):350-62. doi: 10.1158/2159-8290.CD-12-0470. Epub 2013 Jan 3.

5.

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, Yaeger R, Taylor BS, Schultz N, Berger MF, Rosen N, Solit DB.

Cancer Res. 2014 Apr 15;74(8):2340-50. doi: 10.1158/0008-5472.CAN-13-2625. Epub 2014 Feb 27.

6.

Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.

Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy JA, Essner R, Bollag G, Hirth P, Zhang C, Slamon DJ.

Neoplasia. 2010 Aug;12(8):637-49.

7.

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.

Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, Schostack K, Simcox ME, Heimbrook D, Bollag G, Su F.

Cancer Res. 2010 Jul 1;70(13):5518-27. doi: 10.1158/0008-5472.CAN-10-0646. Epub 2010 Jun 15. Erratum in: Cancer Res. 2010 Nov 15;70(22):9527.

8.

Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.

Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M, Winkler J, Koumenis C, Amaravadi RK.

J Clin Invest. 2014 Mar;124(3):1406-17. doi: 10.1172/JCI70454. Epub 2014 Feb 24.

9.

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.

Spender LC, Ferguson GJ, Liu S, Cui C, Girotti MR, Sibbet G, Higgs EB, Shuttleworth MK, Hamilton T, Lorigan P, Weller M, Vincent DF, Sansom OJ, Frame M, Dijke PT, Marais R, Inman GJ.

Oncotarget. 2016 Dec 13;7(50):81995-82012. doi: 10.18632/oncotarget.13226.

10.

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD.

Nature. 2013 Feb 14;494(7436):251-5. doi: 10.1038/nature11814. Epub 2013 Jan 9.

11.

BRAF as a target for cancer therapy.

Dienstmann R, Tabernero J.

Anticancer Agents Med Chem. 2011 Mar;11(3):285-95. Review.

PMID:
21426297
12.

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.

Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA.

Sci Transl Med. 2013 Jul 31;5(196):196ra98. doi: 10.1126/scitranslmed.3005753.

13.

BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.

Perna D, Karreth FA, Rust AG, Perez-Mancera PA, Rashid M, Iorio F, Alifrangis C, Arends MJ, Bosenberg MW, Bollag G, Tuveson DA, Adams DJ.

Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):E536-45. doi: 10.1073/pnas.1418163112. Epub 2015 Jan 26.

14.

BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.

Paoluzzi L, Hanniford D, Sokolova E, Osman I, Darvishian F, Wang J, Bradner JE, Hernando E.

Cancer Med. 2016 Jun;5(6):1183-93. doi: 10.1002/cam4.667. Epub 2016 May 11.

15.

A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.

Graziani G, Artuso S, De Luca A, Muzi A, Rotili D, Scimeca M, Atzori MG, Ceci C, Mai A, Leonetti C, Levati L, Bonanno E, Tentori L, Caccuri AM.

Biochem Pharmacol. 2015 May 1;95(1):16-27. doi: 10.1016/j.bcp.2015.03.004. Epub 2015 Mar 17.

PMID:
25795251
16.

Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma.

Hartsough EJ, Basile KJ, Aplin AE.

Mol Cancer Res. 2014 May;12(5):795-802. doi: 10.1158/1541-7786.MCR-13-0581. Epub 2014 Feb 11.

17.

67-kDa laminin receptor-dependent protein phosphatase 2A (PP2A) activation elicits melanoma-specific antitumor activity overcoming drug resistance.

Tsukamoto S, Huang Y, Umeda D, Yamada S, Yamashita S, Kumazoe M, Kim Y, Murata M, Yamada K, Tachibana H.

J Biol Chem. 2014 Nov 21;289(47):32671-81. doi: 10.1074/jbc.M114.604983. Epub 2014 Oct 7.

18.

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F.

Cancer Res. 2012 Feb 1;72(3):779-89. doi: 10.1158/0008-5472.CAN-11-2941. Epub 2011 Dec 16.

19.

Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.

Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK.

PLoS One. 2012;7(7):e40439. doi: 10.1371/journal.pone.0040439. Epub 2012 Jul 10.

20.

NF1 and Neurofibromin: Emerging Players in the Genetic Landscape of Desmoplastic Melanoma.

Mahalingam M.

Adv Anat Pathol. 2017 Jan;24(1):1-14. Review.

PMID:
27941538

Supplemental Content

Support Center